Arbutus Biopharma (ABUS) Long-Term Investments (2014 - 2024)
Arbutus Biopharma (ABUS) posted Long-Term Investments of $3.0 million for Q3 2024, down 54.59% sequentially from $6.5 million in Q2 2024, and down 71.76% YoY from $10.5 million in Q4 2023.
Arbutus Biopharma (ABUS) Long-Term Investments (2014 - 2024) Analysis & Trends
Arbutus Biopharma has reported Long-Term Investments for 11 years, with the latest figure at $3.0 million in Q3 2024.
- Quarterly Long-Term Investments fell 71.76% year-over-year to $3.0 million in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $3.0 million (down 71.76% YoY) and the FY2023 annual result came in at $6.3 million, down 83.18% from the prior year.
- Long-Term Investments eased to $3.0 million in Q3 2024 per ABUS's latest filing, from $6.5 million in the prior quarter.
- Over five years, Long-Term Investments peaked at $55.4 million in Q3 2022 and troughed at $1.6 million in Q2 2020.
- A 5-year average of $23.9 million and a median of $31.8 million in 2023 frame the typical range for Long-Term Investments.
- The sharpest annual moves came in 2020 and 2021: Long-Term Investments plunged 88.87% in 2020, then soared 2130.5% in 2021.
- Over 5 years, Long-Term Investments stood at $1.6 million in 2020, then jumped by 2130.5% to $35.7 million in 2021, then increased by 4.69% to $37.4 million in 2022, then slumped by 83.18% to $6.3 million in 2023, then tumbled by 52.83% to $3.0 million in 2024.
- According to Business Quant data, Long-Term Investments over the past three periods registered $3.0 million, $6.5 million, and $8.7 million for Q3 2024, Q2 2024, and Q1 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 372.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.17 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Arbutus Biopharma | 922.95 Mn | 830.33 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 2.96 Mn |
| Jun 30, 2024 | 6.53 Mn |
| Mar 31, 2024 | 8.68 Mn |
| Dec 31, 2023 | 6.28 Mn |
| Sep 30, 2023 | 10.50 Mn |
| Jun 30, 2023 | 11.06 Mn |
| Mar 31, 2023 | 31.79 Mn |
| Dec 31, 2022 | 37.36 Mn |
| Sep 30, 2022 | 55.44 Mn |
| Jun 30, 2022 | 50.45 Mn |
| Mar 31, 2022 | 37.36 Mn |
| Dec 31, 2021 | 35.69 Mn |
| Sep 30, 2021 | 35.69 Mn |
| Jun 30, 2021 | 35.69 Mn |
| Mar 31, 2021 | 35.69 Mn |
| Jun 30, 2020 | 1.60 Mn |
| Mar 31, 2020 | 3.22 Mn |
| Sep 30, 2019 | 10.97 Mn |
| Jun 30, 2019 | 14.38 Mn |
| Mar 31, 2019 | 17.68 Mn |